Ernexa Stock Price, News & Analysis

Ernexa Therapeutics (Nasdaq: ERNA) announced it will present new preclinical data for its lead cell therapy candidate ERNA-101 at the AACR Special Conference in Cancer Research on September 20, 2025. The presentation will focus on ERNA-101's ability to reprogram the ovarian tumor microenvironment.

The oral presentation, led by Dr. Michael Andreeff from MD Anderson Cancer Center, will showcase how ERNA-101, an off-the-shelf cell therapy using engineered induced pluripotent stem cells (iPSCs), can potentially activate the immune system to target cancer cells. The therapy demonstrates promise in restoring immune activity in difficult-to-treat ovarian tumors.

Ernexa Therapeutics (NASDAQ: ERNA), a cell therapy company focusing on cancer and autoimmune diseases, reported significant operational improvements for H1 2025. The company achieved a 51% reduction in operating loss to $5.2 million, down from $10.7 million in H1 2024. Total operating expenses decreased by 51% to $5.2 million, with general and administrative expenses dropping 66% to $2.8 million.

The company is advancing two key products: ERNA-101 for ovarian cancer and ERNA-201 for autoimmune disease, both utilizing synthetic allogeneic induced mesenchymal stem cells (iMSCs) for off-the-shelf treatment. Lease expenses saw a dramatic 97% reduction to $0.1 million, primarily due to a sublease termination.

Ernexa Therapeutics (Nasdaq: ERNA), a biotechnology company focused on developing novel cell therapies, will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City.

The company's leadership will showcase their proprietary iMSC platform and two lead programs: ERNA-101 for ovarian cancer and ERNA-201 for autoimmune disease treatment. The presentation will highlight their development of scalable, off-the-shelf cell therapies, with ERNA-101 expected to enter clinical trials by 2026.

Ernexa Therapeutics (Nasdaq: ERNA), a biotechnology company focused on cell therapies for cancer and autoimmune diseases, has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). The company received formal notice from Nasdaq on July 1, 2025, confirming its continued listing status.

CEO Sanjeev Luther reaffirmed the company's commitment to advancing their pipeline, with plans to initiate their first clinical trial in early 2026. The company's focus remains on developing engineered cell therapies for ovarian cancer and autoimmune disease patients.

Ernexa Therapeutics (Nasdaq: ERNA) announced the expansion of its Scientific Advisory Board into a combined Scientific and Medical Advisory Board as it prepares for clinical trials in ovarian cancer and autoimmune disease. The company has appointed two distinguished physicians: Dr. Amir Jazaeri from MD Anderson Cancer Center, who will guide the ovarian cancer program, and Dr. Anna Jonsson from the University of Colorado, who will lead translational strategy for the autoimmune pipeline.

This strategic expansion follows Ernexa's recently strengthened financial position and marks its transition from research to clinical-stage development. The enhanced advisory board will support the company's scientific and clinical strategy as it advances its first oncology and autoimmune programs toward IND-enabling studies.

Ernexa Therapeutics (Nasdaq: ERNA), a company developing cell therapies for cancer and autoimmune diseases, has completed the second closing of its securities purchase agreement, raising $6.0 million in gross proceeds through the issuance of 3,181,145 shares and 622,134 prefunded warrants.

Combined with the initial closing of $1.1 million in April 2025, total gross proceeds reach $7.1 million. The financing, approved by stockholders at the 2025 Annual Meeting, will support working capital needs and debt repayment. A remaining subscription amount of $190,248 for 121,255 shares is pending. The company recently implemented a 1-for-15 reverse stock split on June 12, 2025.

Ernexa Therapeutics (ERNA) announced a 1-for-15 reverse stock split effective June 12, 2025, aimed at regaining compliance with Nasdaq's $1.00 minimum bid price requirement. The company's 110,418,022 outstanding shares will be consolidated to approximately 7,361,201 shares. The split was approved by stockholders on June 2, 2025, and will not affect the total authorized shares or par value. No fractional shares will be issued, with stockholders receiving one whole share instead. Computershare will serve as the exchange agent, managing the conversion process for stockholders. This move, combined with recent financings and corporate restructuring, is part of Ernexa's strategy to strengthen its financial position and maintain capital market access for its clinical programs.

Ernexa Therapeutics (ERNA) will present new data at the ASCO Annual Meeting 2025 showcasing their innovative iMSC-based immunotherapy platform. The technology uses engineered mesenchymal stem cells (iMSCs) that secrete cytokines IL-7 and IL-15 directly into ovarian tumors. Key findings from the study demonstrate that these iMSCs, derived from adult skin cells, successfully:

- Migrated safely into tumor microenvironment
- Triggered strong immune activation
- Converted immunologically "cold" ovarian tumors into "hot" ones
- Significantly reduced tumor burden and extended survival in mouse models

The study, led by Dr. Michael Andreeff from MD Anderson Cancer Center, will be presented on June 2, 2025 in Chicago. The research validates Ernexa's platform technology and its potential to expand treatment options for patients with limited therapeutic choices.

Ernexa Therapeutics (NASDAQ: ERNA) has announced the formation of ErnexaTX2, a wholly owned subsidiary in Texas. This strategic move is designed to support the development of ERNA-101, the company's lead program targeting ovarian cancer. The subsidiary will facilitate ongoing research collaboration with Dr. Michael Andreeff from The University of Texas MD Anderson Cancer Center, an expert in cell therapy and tumor microenvironment.

The new Texas entity will help Ernexa build infrastructure for future clinical operations, including clinical manufacturing, regulatory interactions, and site activation. The company remains on schedule for IND-enabling studies in 2025, with first-in-human trials planned for 2026.